Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial ...
Nasdaq12d
Humacyte, Inc. Announces FDA Approval for SYMVESS as First-in-Class Bioengineered Vascular Conduit for Arterial Injury Repair
“The approval of a vascular conduit that resists infection ... stabbings, blunt trauma, and iatrogenic injuries (injuries caused by medical treatment or examination). Autologous vein, which ...